> In about 25% of [study patients] their lung cancer had already spread to the brain when the study began.
and
> “Lorlatinib is the only ALK TKI that has reported five-year progression-free survival, and even after this time, the majority of patients continue to have their disease controlled, including control of disease in the brain.”
> In about 25% of [study patients] their lung cancer had already spread to the brain when the study began.
and
> “Lorlatinib is the only ALK TKI that has reported five-year progression-free survival, and even after this time, the majority of patients continue to have their disease controlled, including control of disease in the brain.”